Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study

Journal of Gastroenterology and Hepatology
Masanori AtsukawaKatsuhiko Iwakiri

Abstract

This study aimed to evaluate the efficacy and safety of elbasvir/grazoprevir in genotype 1b chronic hepatitis C Japanese patients with chronic kidney disease (CKD), including those undergoing hemodialysis. This post hoc analysis of a multicenter, retrospective study included patients who had received elbasvir/grazoprevir. CKD was defined by an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 . The sustained virologic response (SVR) rate and frequency of treatment-emergent adverse events were assessed in patients with CKD. The study population comprised 155 men and 182 women. The median eGFR level at baseline was 69.6 mL/min/1.73 m2 (range, 3.0-128.5 mL/min/1.73 m2 ). Among the 337 patients, 109 (32.3%) had CKD: 72, 14, and 23 (including 20 hemodialysis) had CKD stages 3, 4, and 5, respectively. The SVR rates according to the baseline CKD stages were 98.1% (51/52) in stage 1, 98.3% (173/176) in stage 2, 93.9% (46/49) in stage 3a, 100% (23/23) in stage 3b, 100% (14/14) in stage 4, and 100% (23/23) in stage 5. All 20 patients undergoing hemodialysis achieved SVR. There was no significant decrease from baseline in the median eGFR level throughout the treatment period among the patients with CKD. The incidence of trea...Continue Reading

References

Nov 30, 1989·The New England Journal of Medicine·G L DavisUNKNOWN Hepatitis Interventional Therapy Group
Nov 30, 1989·The New England Journal of Medicine·A M Di BisceglieJ H Hoofnagle
Dec 18, 1986·The New England Journal of Medicine·J H HoofnagleE A Jones
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Apr 13, 2007·Journal of the American Society of Nephrology : JASN·Kamyar Kalantar-ZadehSander Greenland
Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Jun 30, 2010·Antimicrobial Agents and Chemotherapy·Robert A FridellMin Gao
Dec 4, 2012·Best Practice & Research. Clinical Gastroenterology·Johannes Vermehren, Christoph Sarrazin
Mar 8, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaEric Hughes
Apr 12, 2014·The New England Journal of Medicine·Stefan ZeuzemBarry Bernstein
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 12, 2014·The New England Journal of Medicine·Jordan J FeldBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Fred PoordadBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
May 6, 2014·The New England Journal of Medicine·Peter FerenciUNKNOWN PEARL-IV Study
Jul 7, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaRebecca Redman
Apr 22, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elise J SmoldersDavid M Burger
Feb 23, 2017·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Chisa KondoKatsuhiko Iwakiri
May 1, 2017·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Masanori AtsukawaKatsuhiko Iwakiri
Jan 4, 2018·Liver International : Official Journal of the International Association for the Study of the Liver·Yasuhiro AsahinaNobuyuki Enomoto
Jan 10, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Taeang AraiKatsuhiko Iwakiri
Feb 27, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hideki FujiiNamiki Izumi
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver

❮ Previous
Next ❯

Citations

Feb 20, 2019·Journal of Gastroenterology and Hepatology·Lai WeiRohit Talwani
May 23, 2019·Clinical Pharmacokinetics·Elise J SmoldersDavid M Burger
Dec 29, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Asahiro MorishitaTsutomu Masaki
Oct 11, 2019·Journal of Medical Virology·Tzu-Cheng TsaiChao-Wei Hsu
Jul 11, 2019·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Naoki KawagishiIzumi Haga
Jan 12, 2021·Expert Review of Anti-infective Therapy·Szu-Jen WangMing-Lung Yu
May 2, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ming-Lung YuWan-Long Chuang
Mar 12, 2021·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Masanori AtsukawaKatsuhiko Iwakiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.